Aura Biosciences SVP granted options and RSUs

Aura Biosciences, Inc. reported that Senior Vice President, Finance, Amy Elazzouzi received new equity awards.

Rhea-AI Filing Summary

Aura Biosciences, Inc. reported that Senior Vice President, Finance, Amy Elazzouzi received new equity awards. She was granted stock options for 80,472 shares at an exercise price of $0.00 and 44,528 shares of common stock via restricted stock units, both as compensation awards.

The restricted stock units vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on continued service. The stock options vest with 25% on February 1, 2027, and the remaining 75% in 36 monthly installments, also subject to continued service.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 2 txns

Insider Elazzouzi Amy

Role Senior Vice President, Finance

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	80,472	$0.00	$0.00
Grant/Award	Common Stock	44,528	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 80,472 contracts (Direct); Common Stock — 120,060 shares (Direct)

Footnotes (2)

1. F1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
2. F2. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aura Biosciences (AURA) disclose in this Form 4 for Amy Elazzouzi?

Aura Biosciences disclosed equity awards to Senior Vice President, Finance, Amy Elazzouzi. She received stock options for 80,472 shares and 44,528 restricted stock units, both granted at a price of $0.00 per share as part of her compensation package.

How many stock options did Aura Biosciences (AURA) grant to Amy Elazzouzi?

Amy Elazzouzi was granted stock options covering 80,472 shares of Aura Biosciences common stock. These options vest 25% on February 1, 2027, with the remaining shares vesting pro rata in 36 monthly installments, subject to her continued service with the company.

What restricted stock unit (RSU) award did Amy Elazzouzi receive from Aura Biosciences (AURA)?

She received 44,528 restricted stock units, each representing one share of Aura Biosciences common stock. The RSUs vest in four substantially equal annual installments starting January 15, 2027, provided she continues to serve the company on each scheduled vesting date.

Are Amy Elazzouzi’s Aura Biosciences (AURA) equity awards open-market purchases?

No, the Form 4 shows these are compensation awards, not open-market purchases. Both the 80,472 stock options and 44,528 restricted stock units were granted at $0.00 per share under Aura Biosciences’ 2021 Stock Option and Incentive Plan.

When do Amy Elazzouzi’s Aura Biosciences (AURA) RSUs and options start vesting?

The RSUs begin vesting on January 15, 2027, in four annual installments. The stock options start vesting on February 1, 2027, with 25% vesting then and the remainder vesting monthly over the following 36 months, assuming continued service.

How many Aura Biosciences (AURA) shares does Amy Elazzouzi own after these grants?

Following the RSU grant, Amy Elazzouzi beneficially owns 120,060 shares of Aura Biosciences common stock. Following the stock option grant, she holds options for 80,472 shares, both reported as directly owned in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elazzouzi Amy

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		44,528(1)	A	$0	120,060	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.14	03/02/2026		A		80,472		(2)	03/02/2036	Common Stock	80,472	$0	80,472	D

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.

2. The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Amy Elazzouzi	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.